Page 2212 - Williams Hematology ( PDFDrive )

2186 Part XII: Hemostasis and Thrombosis Chapter 127: Antibody-mediated Coagulation Factor Deficiencies 2187

The role of prothrombin in the generation of lupus anticoagulant 5. Green D, Lechner K: A survey of 215 non-hemophilic patients with inhibitors to Factor
activity initially was suggested from studies of a bleeding patient with VIII. Thromb Haemost 45(3):200–203, 1981.
severe hypoprothrombinemia. However, in the absence of hypoproth- 6. Hogquist KA, Baldwin TA, Jameson SC: Central tolerance: Learning self-control in the
thymus. Nat Rev Immunol 5(10):772–782, 2005.
rombinemia, lupus anticoagulants do not produce a bleeding diathe- 7. Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol 20:
84
sis and bleeding in patients with lupus anticoagulants is uncommon. 197–216, 2002.
Antiprothrombin antibodies are associated with an increased incidence 8. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 12:
991–1045, 1994.
of thrombosis in these patients. In patients with antiprothrombin 9. Rubtsov AV, Swanson CL, Troy S, et al: TLR agonists promote marginal zone B cell
85
antibodies and hypoprothrombinemia, precipitating, noninhibitory activation and facilitate T-dependent IgM responses. J Immunol 180(6):3882–3888,
antibodies are present and prothrombin antigen levels are low, indi- 2008.
cating that the hypoprothrombinemia is the result of rapid clearance 10. Lollar P: Pathogenic antibodies to coagulation factors. Part one: Factor VIII and factor
IX. J Thromb Haemost 2(7):1082–1095, 2004.
86
of antigen–antibody complexes. However, most patients with lupus 11. Dunn AL, Abshire TC: Current issues in prophylactic therapy for persons with hemo-
anticoagulants have demonstrable antiprothrombin antibodies but philia. Acta Haematol 115(3–4):162–171, 2006.
87
do not have hypoprothrombinemia. Thus, antibody-mediated hypo- 12. Franchini M, Lippi G: Acquired factor VIII inhibitors. Blood 112(2):250–255, 2008.
13. White GC 2nd, Kempton CL, Grimsley A, et al: Cellular immune responses in hemo-
prothrombinemia appears to represent a relatively uncommon evolu- philia: Why do inhibitors develop in some, but not all hemophiliacs? J Thromb Haemost
tion of the autoimmune response to prothrombin in patients with lupus 3(8):1676–1681, 2005.
anticoagulants. 14. Lorenzo JI, Lopez A, Altisent C, Aznar JA: Incidence of factor VIII inhibitors in severe
haemophilia: The importance of patient age. Br J Haematol 113(3):600–603, 2001.
15. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS: Recombinant factor VIII for the treat-
ment of previously untreated patients with hemophilia A. Safety, efficacy, and develop-
ANTIBODIES TO COMPONENTS OF ment of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med
328(7):453–459, 1993.
THE PROTEIN C SYSTEM 16. Gouw SC, van der Bom JG, Marijke van den Berg H: Treatment-related risk factors
An acquired inhibitor to protein C associated with a fatal thrombotic of inhibitor development in previously untreated patients with hemophilia A: The
CANAL cohort study. Blood 109(11):4648–4654, 2007.
88
disorder has been reported, but evidently is rare. In contrast, there 17. Astermark J, Berntorp E, White GC, et al: The Malmo International Brother Study
is a relatively high prevalence of pathogenic anti-protein S antibodies. (MIBS): Further support for genetic predisposition to inhibitor development in hemo-
Inhibitory antibodies to protein S were detected in five of 15 patients philia patients. Haemophilia 7(3):267–272, 2001.
with acquired protein S deficiency. Anti–protein S antibodies, but not 18. Astermark J, Oldenburg J, Escobar M, et al: The Malmo International Brother Study
89
(MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A
antibodies to cardiolipin, β -glycoprotein I, prothrombin, or protein C, [see comment]. Haematologica 90(7):924–931, 2005.
2
appear to be a risk factor for acquired activated protein C (APC) resis- 19. Goodeve A: The incidence of inhibitor development according to specific mutations—
tance, defined as APC resistance in the absence of the factor V Leiden and treatment? [review] [8 refs]. Blood Coagul Fibrinolysis 14 Suppl 1:S17–S21, 2003.
90
mutation, and for deep venous thrombosis. Additionally, antibodies to 20. Oldenburg J, Schroder J, Brackmann HH, et al: Environmental and genetic factors
influencing inhibitor development [review] [44 refs]. Semin Hematol 41(1 Suppl 1):
the endothelial cell protein receptor have been identified that are associ- 82–88, 2004.
ated with fetal death in patients with the antiphospholipid syndrome. 91 21. Hendrickson JE, Desmarets M, Deshpande SS, et al: Recipient inflammation affects the
frequency and magnitude of immunization to transfused red blood cells. Transfusion
46(9):1526–1536, 2006.
ACQUIRED ANTIBODIES TO OTHER 22. Hendrickson JE, Chadwick TE, Roback JD, et al: Inflammation enhances consump-
tion and presentation of transfused RBC antigens by dendritic cells. Blood 110(7):
COAGULATION FACTORS 2736–2743, 2007.
23. Meeks SL, Healey JF, Parker ET, et al: Antihuman factor VIII C2 domain antibodies in
Clinically significant antibodies to coagulation factors other than factor hemophilia A mice recognize a functionally complex continuous spectrum of epitopes
VIII, factor V, and prothrombin that produce acquired bleeding disor- dominated by inhibitors of factor VIII activation. Blood 110(13):4234–4242, 2007.
ders are sufficiently rare that they merit case reports, which are only 24. Stowell SR, Henry KL, Smith NH, et al: Alloantibodies to a paternally derived RBC
KEL antigen lead to hemolytic disease of the fetus/newborn in a murine model. Blood
incompletely listed here. In contrast to acquired hemophilia A, acquired 122(8):1494–1504, 2013.
hemophilia B is extremely rare. 92,93 Patients with antifibrinogen anti- 25. Martin F, Kearney JF: Marginal-zone B cells. Nat Rev Immunol 2(5):323–335, 2002.
bodies have been identified either who are asymptomatic with abnor- 26. Navarrete A, Dasgupta S, Delignat S, et al: Splenic marginal zone antigen-presenting
94
95
mal laboratory values or who have abnormal bleeding. Patients with cells are critical for the primary allo-immune response to therapeutic factor VIII in
hemophilia A. J Thromb Haemost 7(11):1816–1823, 2009.
abnormal bleeding associated with acquired inhibitors to factor VII, 27. Zhang AH, Skupsky J, Scott DW: Effect of B-cell depletion using anti-CD20 ther-
96
factor X, factor XI, or factor XIII 98–107 also have been described. The apy on inhibitory antibody formation to human FVIII in hemophilia A mice. Blood
97
98
117(7):2223–2226, 2011.
development of alloantibodies against von Willebrand factor occurs in 28. Bachmann MF, Rohrer UH, Kundig TM, et al: The influence of antigen organization on
patients with type 3 von Willebrand disease in response to treatment B cell responsiveness. Science 262(5138):1448–1451, 1993.
with plasma concentrates that contain von Willebrand factor. Acquired 29. Kempton CL, White GC 2nd: How we treat a hemophilia A patient with a factor VIII
108
inhibitor. Blood 113(1):11–17, 2009.
von Willebrand disease can be caused by adsorption of von Willebrand 30. Meeks SL, Cox CL, Healey JF, et al: A major determinant of the immunogenicity of
factor to tumor cells, loss of high-molecular-weight von Willebrand fac- factor VIII in a murine model is independent of its procoagulant function. Blood
tor multimers at as well as by autoantibodies to von Willebrand factor. 109 120(12):2512–2520, 2012.
31. Hoyer LW, Gawryl MS, de la Fuente B: Immunochemical characterization of factor VIII
inhibitors. Prog Clin Biol Res 150:73–85, 1984.
REFERENCES 32. Lollar P, Parker CG: Subunit structure of thrombin-activated porcine factor VIII.
Biochemistry 28(2):666–674, 1989.
1. Margolius A Jr, Jackson DP, Ratnoff OD: Circulating anticoagulants: A study of 40 cases 33. Fulcher CA, de Graaf Mahoney S, Roberts JR, et al: Localization of human factor FVIII
and a review of the literature. Medicine (Baltimore) 40:145–202, 1961. inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci U S A 82(22):
2. Collins PW, Hirsch S, Baglin TP, et al: Acquired hemophilia A in the United King- 7728–7732, 1985.
dom: A 2-year national surveillance study by the United Kingdom Haemophilia Centre 34. Prescott R, Nakai H, Saenko EL, et al: The inhibitor antibody response is more complex
Doctors’ Organisation. Blood 109(5):1870–1877, 2007. in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibod-
3. Borg JY, Guillet B, Le Cam-Duchez V, et al: Outcome of acquired haemophilia in ies. Recombinate and Kogenate Study Groups. Blood 89(10):3663–3671, 1997.
France: The prospective SACHA (Surveillance des Auto antiCorps au cours de l’Hemo- 35. Scandella D, Mattingly M, de Graaf S, Fulcher CA: Localization of epitopes for human
philie Acquise) registry. Haemophilia 19(4):564–570, 2013. factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood
4. Knoebl P, Marco P, Baudo F, et al: Demographic and clinical data in acquired hemo- 74(5):1618–1626, 1989.
philia A: Results from the European Acquired Haemophilia Registry (EACH2). 36. James JA, Harley JB: B-cell epitope spreading in autoimmunity. Immunol Rev 164:
J Thromb Haemost 10(4):622–631, 2012. 185–200, 1998.
Kaushansky_chapter 127_p2183-2190.indd 2187 17/09/15 3:44 pm